DelveInsight’s, “Aducanumab, Launch Insight, 2019” report provides comprehensive Insight about the Aducanumab's launch. The report covers all the indications for which the Aducanumab is being developed and also provides the competitive landscape for the major indications. The report further includes patent details, forecasted sales till 2022 and post launch market positioning.
The report will provide a clear picture of market positioning of the upcoming launch of Aducanumab and will also provide the insight about how Aducanumab will evolve in the market as well as within its respective class.Report provides detailed information of clinical trials that have been or are being conducted for this product. Analysis and Insightful information around the clinical trials is provided by assessment of the trial results.
Attribute analysis carried out by our analysts helps in understanding how the upcoming launch scores itself in comparison to other competitors (both marketed and pipeline). The scoring and analysis has been based upon scrutinizing data from all key clinical trials for the product. A head to head comparison with marketed products if available is scanned thoroughly. Further, analyzing data of other competitors with regards to the product also assists in proper scoring of the product in its space.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
• Detailed product description including its chemical properties, molecule type and mechanism of action
• Detailed description of non-clinical and clinical studies for all the indications
• Patent expiry analysis of the drug along with other competitors in the market
• Forecasted sales till 2022
• Aducanumab market positioning analysis
• Aducanumab class share evolution
Aducanumab of action
• Indication 1
• Indication 2
• Indication 1
• Indication 2
Product Developmental Activities
• Mergers & Acquisitions
Aducanumab Market Evolution
Aducanumab Class Share Evolution
Aducanumab Market Positioning
Patent Expiry Analysis
Competitive Landscape for the Aducanumab in major indications
List of Tables
Table 1: Aducanumab, Heat Map
Table 2: Clinical Trial Landscape
Table 3: Clinical Efficacy Data from Cross Trials
Table 4: Competitive Landscape for Aducanumab in Indication 1
Table 5: Competitive Landscape for Aducanumab in Indication 2
List of Figures
Figure 1: Aducanumab Developmental Milestones
Figure 2: Aducanumab Sales Forecast till 2023
Figure 3: Aducanumab Class Share Evolution
Figure 4: Comparative analysis of Aducanumab with marketed products in the same class
Figure 5: Patent Expiry Analysis
It is a raw material for nervous system and is used in the production of Tropisetron Hydrochloride.Market Analysis and Insights Global Granisetron Hydrochloride API MarketDue to the COVID19 pandemic the global Granisetron Hydrochloride API market size is estimated to be worth US million in 2022 and is forecast to a readjusted size of US million by 2028 with a CAGR of during the review period.
The small volume bioreactors enable the biomass growth extracellular metabolite production solidstate fermentation and biocatalytic processes in a controlled open system.Market Analysis and Insights Global Lab Scale Bioreactor MarketDue to the COVID19 pandemic the global Lab Scale Bioreactor market size is estimated to be worth US million in 2022 and is forecast to a readjusted size of US million by 2028 with a CAGR of during the review period.
Market Analysis and Insights Global Ocular Excipients MarketDue to the COVID19 pandemic the global Ocular Excipients market size is estimated to be worth US million in 2022 and is forecast to a readjusted size of US million by 2028 with a CAGR of during the review period.